

In addition to being genetically stable over time, VEGF is also continuously expressed throughout the development of many tumor types. In fact, VEGF is the only angiogenic factor known to be present throughout the entire tumor life cycle. As the tumor develops, it may begin to activate secondary angiogenic pathways, such as basic fibroblast growth factor (bFGF), transforming growth factor beta (TGFβ), placental growth factor (PlGF), and platelet-derived endothelial cell growth factor (PD-ECGF). As these secondary pathways emerge, VEGF continues to be overexpressed and remains one of the critical mediators of angiogenesis.7, 10-12